RLYB vs OMEX Comparison

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Odyssey Marine Exploration Inc is a deep-ocean exploration company. The company provides specialized mineral exploration, project development, and marine services to clients. It is engaged in the discovery, validation, and development of subsea mineral deposits in a socially and environmentally responsible manner. The company works with governments to identify mineral resources in Exclusive Economic Zones, focusing on phosphorite (fertilizer) and polymetallic nodules (battery metals) projects. Its projects include the ExO Phosphate project, CIC, Ocean Minerals, and the LIHIR Gold project.